QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients

Khawcharoenporn, Thana; Phetsuksiri, Benjawan; Rudeeaneksin, Janisara; Srisungngam, Sopa; Apisarnthanarak, Anucha

doi:10.7883/yoken.jjid.2016.480

Cited by 5 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Earlier studies have evaluated IGRA during preventive treatment but not after completion of treatment (Bastos et al, 2013;Johnson et al, 2014); this may lead to false results because IFN-g responses may not have changed at that time. Our findings are consistent with those of a previous study conducted on HIV-infected patients, which reported that QFT-GIT reversion is delayed or does not occur 2 years after isoniazid preventive treatment (Khawcharoenporn et al, 2017). The decline in IFN-g level among silicosis patients during T1 may be explained by the eradication of latent TB infection by the immune system (Higuchi et al, 2008).…”

Section: Discussionsupporting

confidence: 92%

Preventive tuberculosis treatment effect on QuantiFERON TB-Gold in-tube testing in a high tuberculosis-endemic country: A clinical trial

Yang

Ruan

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Background: Whether T-cell interferon-g responses to Mycobacterium tuberculosis-specific antigens can be influenced by tuberculosis preventive treatment in a high-endemic country is uncertain. Methods: In this prospective, open-label, controlled study, 513 individuals with silicosis were randomly selected for TB preventive treatment with rifapentine and isoniazid or for observation. QuantiFERON-TB Gold in-tube (QFT-GIT) assay was used to measure IFN-g response to M. tuberculosis antigens at baseline (T0) and at 6 (T1) and 33 (T2) months after completion of therapy. Results: A total of 220 subjects were included in the final analysis: 105 and 115 in the prevention and observation arms, respectively. The proportions of QFT-GIT reversion from baseline to T1 were similar in the prevention and observation arms (18.4% vs 12.8%, P = 0.566). However, reversion from baseline to T2 was more frequent in the prevention arm than in the observation arm, but the difference was not significant (24.2% vs 6.3%, P = 0.881). No significant difference was observed in the quantitative responses of QFT-GIT between the two arms during follow-up at T1 (P = 0.648) and T2 (P = 0.918). Conclusions: Preventive tuberculosis treatment has no effect on interferon-g responses measured by serial QFT-GIT assays in a high tuberculosis-endemic country. Clinical Trials Registration: http://www.clinicaltrials.gov NCT02430259.

show abstract

Section: Discussionsupporting

confidence: 92%

Preventive tuberculosis treatment effect on QuantiFERON TB-Gold in-tube testing in a high tuberculosis-endemic country: A clinical trial

Yang

Ruan

et al. 2020

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…One (2.0%) study reported an adherence rate within the range of the 1st quartile, 10 (19.2%) in the 2nd quartile, 25 (48.1%) in the 3rd quartile and 16 (30.8%) in the 4th quartile 25 - 27 , 29 - 31 , 33 - 38 , 40 - 42 , 46 - 52 , 54 - 61 , 63 - 65 , 67 , 70 - 73 , 77 - 79 , 80 - 84 , 87 , 88 , 90 , 91 , 95 .…”

Section: Resultsmentioning

confidence: 98%

“…Most of the included studies (n = 49) did not specify patient profiles 24 - 33 , 35 - 37 , 40 - 44 , 47 , 49 , 51 , 52 , 54 , 55 , 57 - 59 , 60 , 63 - 65 , 67 , 68 , 70 , 71 , 77 , 79 , 81 - 87 , 89 , 90 , 93 , 94 , four studies involved patients with inflammatory bowel disease or immune-mediated inflammatory diseases 72 , 73 , 76 , 80 , four involved human immunodeficiency virus (HIV)-positive adults 56 , 61 , 74 , 91 , four involved patients who transplanted or had transplants 34 , 50 , 62 , 66 , and six involved health professionals 38 , 39 , 45 , 48 , 78 , 88 .…”

Section: Resultsmentioning

confidence: 99%

“…Regarding the various treatment alternatives for LTBI globally, among the studies analyzed, 53 used INH for 9 months 24 - 28 , 30 - 34 , 38 - 46 , 49 - 54 , 58 , 61 , 63 , 64 , 67 , 69 , 72 - 74 , 76 , 77 - 79 , 80 , 81 , 82 - 87 , 89 , 91 , 92 , 94 , 95 , 40 used INH for 6 months 24 , 26 , 27 , 29 , 34 - 36 , 39 , 42 - 44 , 47 - 49 , 53 , 55 , 56 , 57 , 59 - 62 , 64 , 65 , 67 , 68 , 70 , 71 , 72 , 74 , 75 , 84 , 86 - 90 , 93 , 94 , 95 , and two used INH for 12 months 66 . Rifampicin monothera...…”

Section: Resultsmentioning

confidence: 99%

“…In other participants, the rates did not exceed 10%, and most remained below 5% 28 , 36 , 37 , 49 , 56 , 57 , 61 - 63 , 71 , 75 , 76 , 79 , 80 , 83 , 85 - 87 , 89 , 93 . Another 17 studies evaluated the effectiveness of INH treatment and did not identify active TB after the follow-up period 30 , 34 , 41 , 46 , 48 , 50 , 53 , 55 , 60 , 66 , 72 , 73 , 84 , 88 , 91 , 92 , 94 ( ).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review

Sodré-Alves,

Toledo,

Zimmermann

et al. 2024

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Background: The treatment strategy for latent tuberculosis infection is to reduce the number of tuberculosis cases and consequently reduce the transmission of pathogenic bacteria. This study aimed to determine the safety, effectiveness, and adherence of isoniazid use for latent tuberculosis infection treatment. Methods: To identify studies on isoniazid use for latent tuberculosis infection, five electronic databases were searched. The methods and results are presented in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: Most studies (53) used isoniazid for 9 months. The prevalence of use and adherence to treatment varied considerably (18% to 100%), and were evaluated by participant completion of isoniazid treatment for latent tuberculosis infection. The adverse events most frequently reported were hepatotoxicity, gastric intolerance, and neuropathy; the rates of occurrence ranged from < 1% to 48%. In the studies that evaluated the effectiveness of isoniazid for latent tuberculosis infection, the rate varied from 0 to 19.7% for patients who did not have active tuberculosis after the follow-up period. Conclusions: The importance of maintaining follow up for patients using isoniazid should be emphasized due to the risk of developing adverse events. Despite the treatment challenges, the rates of patients who used isoniazid and developed active tuberculosis during the follow-up period were low. We believe that isoniazid continues to contribute to tuberculosis control worldwide, and better care strategies are required.

show abstract

Reversion of QuantiFERON-TB Gold In-Tube test in individuals with and without prophylactic treatment for latent tuberculosis infection: A systematic review and meta-analysis

Zhang

Xin

et al. 2018

Journal of Infection

View full text Add to dashboard Cite

QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients

Cited by 5 publications

References 18 publications

Preventive tuberculosis treatment effect on QuantiFERON TB-Gold in-tube testing in a high tuberculosis-endemic country: A clinical trial

Preventive tuberculosis treatment effect on QuantiFERON TB-Gold in-tube testing in a high tuberculosis-endemic country: A clinical trial

Isoniazid use, effectiveness, and safety for treatment of latent tuberculosis infection: a systematic review

Reversion of QuantiFERON-TB Gold In-Tube test in individuals with and without prophylactic treatment for latent tuberculosis infection: A systematic review and meta-analysis

Contact Info

Product

Resources

About